Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling

Fig. 1

High expression of CRABP-II is associated with poor prognostics and drug resistance in human PDAC. A Kaplan–Meier overall survival curves for PDAC patients based on CRABP-II levels. Data shown here are from Kaplan–Meier Plotter database. B, C CRABP-II expression in paired primary and relapsing PDAC (n = 12) assessed by immunochemistry. All patients received gemcitabine-based chemotherapy after surgery. Immunoreactivity in (C) was calculated by multiplying the percentage of positive epithelium cells and the score of staining intensity (intensity: 0, undetectable; 1, weak; 2, moderate; and 3, strong). Paired sample t-test was used to determine the difference between primary group and relapsing group. Up panel in (B): black arrow denotes the poorly differentiated tumor; blue arrow denotes the well differentiated tumor. D, E Establishment of gemcitabine resistant cell lines using BxPC3 as parental line. Gemcitabine sensitivities of GR2000, GR4000 and BxPC3 cells were assessed by MTT assay (D). CRABP-II levels in these lines were detected by western blots (E). F Gemcitabine sensitivity comparison of Panc-1, CRABP-II knockout (CIIKO) and CRABP-II re-expressing (CIIOE) cells by MTT assays. G Gemcitabine induced cell apoptosis assessed by cleaved caspase-3 blots

Back to article page